Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) — ALD518-010

Acute GvHD Clinical Trial

Official title:
An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in Subjects With Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acute GvHD

Clinical Trial Details

NCT number	NCT01530256
Study type	Interventional
Source	CSL Behring
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	March 2012
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02806947` - A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)	Phase 2
Completed	`NCT02631993` - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia	N/A
Not yet recruiting	`NCT03701698` - Ruxolitinib and Steroid as First Line Therapy for Acute GVHD	Phase 2
Recruiting	`NCT04373057` - Prebiotic Galacto-oligosaccharide and Acute GVHD	Phase 1/Phase 2
Completed	`NCT04645667` - Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Completed	`NCT00350181` - Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT	Phase 2
Recruiting	`NCT02611180` - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Recruiting	`NCT05263999` - A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)	Phase 3